Aprea Pharmaceuticals Expands Global Patent Protection To Strengthen DDR Oncology Pipeline (APHA)

Aprea Pharmaceuticals (APHA) announced on February 13, 2026, the expansion of its global patent protection for its lead DDR (double-strand break) cancer therapy, AP-223. The update extends protection in key markets including the EU, Japan, and China, securing potential exclusivity through 2034. The move follows positive Phase 2 results in solid tumors and is expected to support the company’s ongoing clinical trials and potential future sales. The company cited the extension as a strategic response to global competition and a step to solidify its position in the oncology pipeline. AP-223’s Phase 2 trial achieved a 40% overall response rate in heavily pretreated patients, with a median progression-free survival of 12 months, according to the filing.